Table 2.
Ref. | Year | Design | No pts. | ARDS n (%) | Predicts ARDS | Results |
IL-6 | ||||||
Donnelly et al[37] | 1994 | P-coh | 15 | 7 (49%) | N | [IL-6] is not significantly different in ARDS |
Meade et al[45] | 1994 | P-coh | 25 | 9 (36%) | N | [IL-6] is higher in patients with ARDS after onset of symptoms; does not predict development of ARDS |
Raymondos et al[48] | 2012 | P-coh | 24 | 7 (29%) | Y | [IL-6] is significantly higher in patients at high risk for ARDS |
Sousa et al[51] | 2015 | P-coh | 99 | 19 (19%) | Y | [IL-6] is significantly higher at 72 h post injury |
IL-8 | ||||||
Donnelly et al[37] | 1994 | P-coh | 15 | 7 (49%) | Y | [IL-8] is significantly higher in patients with ARDS, starting at 16 h post injury |
Meade et al[45] | 1994 | P-coh | 25 | 9 (36%) | N | [IL-8] is higher in patients with ARDS after onset of symptoms; does not predict development of ARDS |
Raymondos et al[48] | 2012 | P-coh | 24 | 7 (29%) | Y | [IL-8] is significantly higher in patients at high risk for ARDS |
IL-10 | ||||||
Neidhardt et al[54] | 1997 | P-cc | 417 | 19 (5%) | N | [IL-10] is not related to the development of ARDS |
Sherry et al[14] | 1996 | R-cc | 66 | 5 (8%) | N | [IL-10] is not related to the development of ARDS |
Sousa et al[51] | 2015 | P-coh | 99 | 19 (19%) | Y | [IL-10] is significantly higher in patients with ARDS upon admission, at 24 + 48 + 72 h post injury |
Spielmann et al[57] | 2001 | P-cc | 47 | 5 (11%) | N | [IL-10] is not related to the development of ARDS |
TNF-αα | ||||||
Donnelly et al[37] | 1994 | P-coh | 15 | 7 (49%) | N | [TNF-α] below detection limit |
Meade et al[45] | 1994 | P-coh | 25 | 9 (36%) | N | [TNF-α] below detection limit |
Sousa et al[51] | 2015 | P-coh | 99 | 19 (19%) | N | [TNF-α] is not related to the development of ARDS |
IL-1β | ||||||
Donnelly et al[37] | 1994 | P-coh | 15 | 7 (49%) | N | [IL-1β] below detection limit |
Meade et al[45] | 1994 | P-coh | 25 | 9 (36%) | N | [IL-1β] below detection limit |
P-coh: Prospective cohort study; P-cc: Prospective case-control study; R-cc: Retrospective case-control study; IL: Interleukin; TNF: Tumor necrosis factor; Pts: Patients; Y: Yes; N: No.